XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of stock-based compensation expense included in operating expenses on condensed consolidated statements of operations related to share-based payment awards

The following table summarizes the stock-based compensation expense included in operating expenses on our condensed consolidated statements of operations related to stock options and employee stock purchases for the three months ended March 31, 2023 and 2022, which was allocated as follows:

 

 

 

Three Months Ended March 31,

 

(In thousands)

 

2023

 

 

2022

 

Research and development

 

$

1,306

 

 

$

855

 

General and administrative

 

$

1,655

 

 

 

837

 

Stock-based compensation expense included in operating expenses

 

$

2,961

 

 

$

1,692

 

Schedule of assumptions used to estimate the fair value of service-based stock options granted The fair value of service-based stock options granted during the three months ended March 31, 2023 and 2022 has been estimated at the date of grant using the Black Scholes option-pricing model with the following assumptions:

 

 

Three Months Ended March 31,

 

 

2023

 

2022

Dividend yield

 

0%

 

0%

Expected volatility range

 

81.53% to 81.64%

 

77.70% to 78.20%

Risk-free interest rate range

 

3.42% to 4.10%

 

1.69% to 2.23%

Expected term

 

6 years

 

5.5 years

 

Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan

The fair value of employees’ stock purchase rights during the three months ended March 31, 2023 and 2022 has been estimated using the Black Scholes option-pricing model with the following assumptions:

 

 

Three Months Ended March 31,

 

 

2023

 

2022

Dividend yield

 

0%

 

0%

Expected volatility range

 

61.04% to 81.08%

 

50.90% to 61.40%

Risk-free interest rate range

 

0.09% to 4.76%

 

0.09% to 0.40%

Expected term range

 

6 months to 12 months

 

6 months to 12 months